Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1)

Journal of Cellular Physiology

Volumn 221, Issue 3, 2009, Pages 778-788

  Pereira, Barry P ^a   Zhou, Yefang ^b,f   Gupta, Anurag ^b   Leong, David T ^b   Aung, Khin Zarchi ^a   Ling, Ling ^c   Pho, Robert W H ^a   Galindo, Mario ^d   Salto Tellez, Manuel ^b   Stein, Gary S ^e   Cool, Simon M ^a,c   Van Wijnen, Andre J ^b,e   Nathan, Saminathan S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^d UNIVERSITY OF CHILE   (Chile)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD63 ANTIGEN; CD71 ANTIGEN; CELL MARKER; CYCLIN A; CYCLIN DEPENDENT KINASE 1; CYCLIN E; ENDOGLIN; HERMES ANTIGEN; MOLECULAR MARKER; NOCODAZOLE; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR RUNX2; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; KI 67 ANTIGEN; LEUKOCYTE ANTIGEN; OSTEOCALCIN; RUNX2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CELL SYNCHRONIZATION; CHROMOSOME ABERRATION; CHROMOSOME G BAND; CONTROLLED STUDY; DEREGULATION; DIAGNOSTIC TEST; DNA DAMAGE; ETHNIC DIFFERENCE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MESENCHYMAL STEM CELL; MESENCHYME; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; XENOTRANSPLANTATION; ADOLESCENT; ANIMAL; ASIAN; BONE MINERALIZATION; CELL CYCLE; CELL DEDIFFERENTIATION; CHILD; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ADOLESCENT; ANIMALS; ANTIGENS, CD; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIFICATION, PHYSIOLOGIC; CELL CYCLE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHROMOSOME ABERRATIONS; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; MICE; MICE, SCID; NOCODAZOLE; OSTEOBLASTS; OSTEOCALCIN; OSTEOSARCOMA; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70449727683     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21921     Document Type: Article

References (51)

1. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinzoni F, Mercuri M, Monti C. 1993. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72:3227-3238.
2. Beijamin R, Chawla S, Carrasco H, Raymond A, Murray J, Armen T, Patel S, Wallace S, Ayala A, Papadopoulos N. 1992. Preoperative chemotherapy for osteosarcoma with intravenous Adriamycin and intoa-arterial cis-platinum. Ann Oncol Suppl 3:3-6.
3. Berman SD, Calo E, Landman AS, Danielian PS, Miller ES, West JC, Fonhoue BD, Caron A, Bronson R, Bouxsein ML, Mukherjee S, Lees JA. 2008a. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 105:11851-11856.
4. Berman SD, Yuan TL, Miller ES, Lee EY, Caron A, Lees JA. 2008b. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol Cancer Res 6:1440-1451.
5. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790. (Pubitemid 34111386)
6. Bodo M, Lilli C, Bellucci C, Carinci P, Calvitti M, Pezzetti F, Stabellini G, Bellocchio S, Balducci C, Carinci F, Baroni T. 2002. Basic fibroblast growth factor autocrine loop controls human osteosarcoma phenotyping and differentiation. Mol Med 8:393-404. (Pubitemid 35346219)
7. Chandar N, Billig B, McMaster J, Novak J. 1992. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65:208-214.
8. Coffin CM, Lowichik A, Zhou H. 2005. Treatment effects in pediatric soft tissue and bone tumors: Practical considerations for the pathologist. Am J Clin Pathol 123:75-90. (Pubitemid 40066173)
9. Deshpande A, Hinds PW. 2006. The retinoblastoma protein in osteoblast differentiation and osteosarcoma. Curr Mol Med 6:809-817. (Pubitemid 44725572)
10. Fuchs B, Pritchard DJ. 2002. Etiology of osteosarcoma. Clin Orthop Relat Res 397:40-52.
11. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ. 2005. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 280:20274-20285. (Pubitemid 40776725)
12. Gao R, Price DK, Sissung T, Reed E, Figg WD. 2008. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 7:1246-1250.
13. Gillette JM, Larochelle A, Dunbar CE, Lippincott-Schwartz J. 2009. Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nat Cell Biol 11:303-311.
14. Gilman PA, Wang N, Fan SF, Reede J, Khan A, Leventhal BG. 1985. Familial osteosarcoma associated with 13;14 chromosomal rearrangement. Cancer Genet Cytogenet 17:123-132. (Pubitemid 15028246)
15. Grimer RJ, Taminiau AM, Cannon SR, Surgical Subcommitte of the European Osteosarcoma Intergroup. 2002. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 84:395-400.
16. Haasters F, Prall WC, Anz D, Bourquin C, Pautke C, Endres S, Mutschler W, Docheva D, Schieker M. 2009. Morphological and immunocytochemical characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. J Anat 214:759-767.
17. Haslam SI, Van Hul W, Morales-Piga A, Balemans W, San-Millan JL, Nakatsuka K,Willems P, Haites NE, Ralston SH. 1998. Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13:911-917. (Pubitemid 28265268)
18. Hatakeyama M, Weinberg RA. 1995. The role of RB in cell cycle control. Prog Cell Cycle Res 1:9-19.
19. Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PCS, Figg WD, Lee EJ, Chowbay B. 2007. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8:567-575. (Pubitemid 46939582)
20. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, Stein GS, Lian JB, Jones SN. 2006. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172:909-921.
21. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. 2004. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14:1-41. (Pubitemid 38581526)
22. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. 1991. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 270:8-14.
23. Meyers PA, Gorlick R. 1997. Osteosarcoma. Pediatr Clin North Am 44:973-989.
24. Mirabello L, Troisi RJ, Savage SA. 2009. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543.
25. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. (Pubitemid 14203433)
26. Nakayama Y, Kato N, Nakajima Y, Shimizu E, Ogata Y. 2004. Effect of TNF-alpha on human osteosarcoma cell line Saos2-TNF-alpha regulation of bone sialoprotein gene expression in Saos2 osteoblast-like cells. Cell Biol Int 28:653-660. (Pubitemid 39423674)
27. Nathan SS, DiResta GR, Casas-Ganem JE, Hoang BH, Sowers R, Yang R, Huvos AG, Gorlick R, Healey JH. 2005. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11:2389-2397. (Pubitemid 40490200)
28. Nathan SS, Gorlick R, Bukata S, Chou A, Morris CD, Boland PJ, Huvos AG, Meyers PA, Healey JH. 2006. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer 107:1607-1616. (Pubitemid 44546922)
29. Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, Sowers R, DiResta GR, Gorlick R, Healey JH. 2008. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 26:1520-1525.
30. Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, Pho RWH, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. 2009. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36:153-158.
31. Parkin DM, Stiller CA, Nectoux J. 1993. International variations in the incidence of childhood bone tumours. Int J Cancer 53:371-376. (Pubitemid 23047882)
32. Petkovic I, Cepulic M. 1996. Chromosome aberrations in two osteosarcoma. Cancer Genet Cytogenet 158:91.
33. Picci P, Sangiorgi L, Bahamonde L, Aluigi P, Bibiloni J, Zavatta M, Mercuri M, Briccoli A, Campanacci M. 1997. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 8:899-903.
34. Polito P, Cin P, Debiec-Rychter M, Hagemeijer A, 2003. Human solid tumors: Cytogenetic techniques. In: Swansbery J, editor. Cancer cytogenetics methods and protocols. Totowa, New Jersey: Humana Press. pp 135-150.
35. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 2003. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 63:5357-5362.
36. Settakorn J, Lekawanvijit S, Arpornchayanon O, Rangdaeng S, Vanitanakom P, Kongkarnka S, Cheepsattayakorn R, Ya-In C, Thorner PS. 2006. Spectrum of bone tumors in Chiang Mai University Hospital, Thailand according to WHO classification 2002: A study of 1,001 cases. J Med Assoc Thai 89:780-787.
37. Stiller CA, Bunch KJ, Lewis IJ. 2000. Ethnic group and survival from childhood cancer: Report from the UK Children's Cancer Study Group. Br J Cancer 82:1339-1343.
38. Tadokoro T, Kobayashi N, Zmudzka BZ, Ito S, Wakamatsu K, Yamaguchi Y, Korossy KS, Miller SA, Beer JZ, Hearing VJ. 2003. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. FASEB J 17:1177-1179.
39. Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. 1978. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 53:695-700.
40. Teplyuk NM, Galindo M, Teplyuk VI, Pratap J, Young DW, Lapointe D, Javed A, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 2008. Runx2 regulates Gprotein-coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem 283:27585-27597.
41. Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW. 2001. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 8:303-316.
42. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, Diyagama D, Grim JE, Clurman BE, Bowtell DDL, Lee JS, Gutierrez GM, Piscopo DM, Carty SA, Hinds PW. 2004. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 167:925-934.
43. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
44. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, Alt FW, McMahon AP, Orkin SH. 2008. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22:1662-1676.
45. Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q, Ng HH, Karsenty G, de Crombrugghe B, Yeh J, Li B. 2006. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172:115-125.
46. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X. 2002. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22:7982-7992. (Pubitemid 35217306)
47. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, Peck SD, Stevens SL, Kelly CM, Camozzi AB. 2003. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 10:498-507. (Pubitemid 40486912)
48. Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK, Lee SH, Yang X, Xie R, Javed A, Underwood JM, Furcinitti P, Imbalzano AN, Penman S, Nickerson JA, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 2007a. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445:442-446.
49. Young DW, Hassan MQ, Yang XQ, Galindo M, Javed A, Zaidi SK, Furcinitti P, Lapointe D, Montecino M, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 2007b. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci USA 104:3189-3194. (Pubitemid 46364135)
50. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. 2007. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 104:19861-19866.
51. Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR. 2001. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 106:97-106. (Pubitemid 32701077)